1. Home
  2. TBPH vs PDFS Comparison

TBPH vs PDFS Comparison

Compare TBPH & PDFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Theravance Biopharma Inc.

TBPH

Theravance Biopharma Inc.

HOLD

Current Price

$19.87

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Logo PDF Solutions Inc.

PDFS

PDF Solutions Inc.

HOLD

Current Price

$31.46

Market Cap

1.2B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
TBPH
PDFS
Founded
2013
1992
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
EDP Services
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
1.2B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
TBPH
PDFS
Price
$19.87
$31.46
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
3
Target Price
$27.80
$31.00
AVG Volume (30 Days)
376.6K
300.2K
Earning Date
02-25-2026
02-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.58
N/A
Revenue
$80,327,000.00
$206,706,000.00
Revenue This Year
$70.78
$24.23
Revenue Next Year
N/A
$19.28
P/E Ratio
$32.64
N/A
Revenue Growth
27.12
21.23
52 Week Low
$7.90
$15.91
52 Week High
$21.03
$36.99

Technical Indicators

Market Signals
Indicator
TBPH
PDFS
Relative Strength Index (RSI) 54.78 44.90
Support Level $18.78 $33.50
Resistance Level $21.03 $35.21
Average True Range (ATR) 0.81 1.63
MACD -0.15 -0.43
Stochastic Oscillator 45.60 9.82

Price Performance

Historical Comparison
TBPH
PDFS

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

About PDFS PDF Solutions Inc.

PDF Solutions Inc offers products and services designed to empower engineers and data scientists across the semiconductor ecosystem to improve the yield, quality, and profitability of their products. The solutions combine proprietary software, physical intellectual property (or IP) for integrated circuit (or IC) designs, electrical measurement hardware tools, various methodologies, and professional services. The company's products and services are sold to integrated device manufacturers (or IDMs), fabless semiconductor companies, foundries, outsourced semiconductor assembly and test (or OSATs), and system houses.

Share on Social Networks: